Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerProstate Radiotherapy in the Era of Advanced Imaging and Precision MedicineThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsContemporary Management of Prostate CancerPSA and beyond: alternative prostate cancer biomarkersPotential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerWhat is the Need for Prostatic Biomarkers in Prostate Cancer Management?Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screeningActive surveillance monitoring: the role of novel biomarkers and imagingBiomarkers in prostate cancer: what's new?Open tubular lab-on-column/mass spectrometry for targeted proteomics of nanogram sample amountsExpression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohortHow Precisely Can Prostate Cancer Be Managed?Can contemporary patients with biopsy Gleason score 3+4 be eligible for active surveillance?Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.Reduced expression of PinX1 correlates to progressive features in patients with prostate cancer.Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.Translating RNA sequencing into clinical diagnostics: opportunities and challenges.Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohortLow-grade prostate cancer diverges early from high grade and metastatic disease.Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men.Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?The need for a personalized approach for prostate cancer management.Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.Risk stratification of prostate cancer in the modern era.The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionDysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies.High-risk prostate cancer-classification and therapy.Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohortValidation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.RNA biomarkers to facilitate the identification of aggressive prostate cancerCost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.Applying precision medicine to the active surveillance of prostate cancer.Chitooligosaccharides promote radiosensitivity in colon cancer line SW480.Personalized prostate cancer care: from screening to treatment.Clinically available RNA profiling tests of prostate tumors: utility and comparisonBiomarkers in prostate cancer surveillance and screening: past, present, and future.
P2860
Q26738703-01240EC5-91CB-4D43-95FB-E14669C43917Q26749961-B4307FE3-C4AE-46BE-8CCB-B651B51CE97BQ26750672-319680D0-7187-4DD5-A23B-EC4C11BECEEEQ26752510-E1406392-AACC-4220-9391-A77E34247B39Q26767456-7BF1D8A4-EC6B-4AC0-B8E9-D716E1ECE96DQ26770646-7FDA6613-06A6-4C22-A6E7-29AB46373781Q26784517-C65CB285-8DE1-41C9-9216-38F4F344BFF5Q26798425-EA7F35E6-FE5E-4E8D-AADD-9D7EB29C7285Q27001043-D3ACD83F-37FA-4764-BA0D-524F8BEF04AAQ27007131-D25E4F4F-95EF-4A4C-82FD-95EECC6AC8A0Q27026210-EA9A5454-8BFB-4C50-A1D4-B6250808A1A7Q27312175-8671F41F-4C02-402B-A8F5-353E8E8DEA55Q27331050-B684E64D-0D0F-43E2-8846-8508BF695413Q28078942-310E0718-E696-4731-B62B-DDE1E01DE884Q28543448-A21AD60F-DCE4-417A-AA3E-50DC552C1A21Q33761801-C3CF74A7-B83E-494D-8A24-129AEC86F0EFQ33762586-1671CACB-BD71-47FC-AF27-20604902E22CQ33905899-7D60B86D-465F-48B0-9D3F-83ABDA41EBB4Q34519034-4DFB543A-EC1D-4DA7-92B4-302483D80F33Q34807402-5338579A-3BA8-4C29-AF7D-5BFFA41500F0Q35180364-3A9B9663-8725-47D6-B584-7799317AF5F8Q35256915-46C0B906-2FB4-429D-A998-76215E3FB58FQ35536948-A05B163C-6A23-4A17-866B-6DBD486A3D68Q35625815-16E2154B-A25D-430C-8823-CCAB8A51F5ABQ35678391-3B0D8EEF-962B-4752-88B5-130E385F7279Q35680101-F0699269-A618-457A-A7BC-D1BFB25A8EF0Q35706611-B52CCF0A-93FF-420A-A761-BDCC89AF498AQ35764986-406177A0-9CCB-414B-AE99-84B4075B3BBDQ35852107-3A8DED42-34DB-4B01-8396-DA7D799CC838Q35869811-ED822A11-6A22-42D7-81F7-071CEA8FF033Q35909631-3D9C2457-2FBE-46DE-977F-F9FA36D000CDQ36022437-0F982CDF-A5D7-463F-B27D-87CCF3129E97Q36201978-5AED4B5F-796B-47CD-838E-C110A1864E5DQ36260364-B41FB8C6-24FD-4AED-8248-CF33D56DBE17Q36371617-AD45C79A-D880-48BF-837D-C3D415B92C25Q36592871-E7F4D94E-105B-4AE6-A1F2-CD313D02CDA8Q36969876-C9E699FA-8496-427F-8718-B7BD8C2B3063Q37113160-F825DF33-497B-40C2-91B0-60A708D086F5Q37113181-9070B3B0-1CD8-42CE-A250-332D32867CABQ37300931-C502CC0B-E46A-4750-8E71-86B0E21FAC2E
P2860
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Validation of a cell-cycle pro ...... emporary prostatectomy cohort.
@en
Validation of a cell-cycle pro ...... emporary prostatectomy cohort.
@nl
type
label
Validation of a cell-cycle pro ...... emporary prostatectomy cohort.
@en
Validation of a cell-cycle pro ...... emporary prostatectomy cohort.
@nl
prefLabel
Validation of a cell-cycle pro ...... emporary prostatectomy cohort.
@en
Validation of a cell-cycle pro ...... emporary prostatectomy cohort.
@nl
P2093
P356
P1476
Validation of a cell-cycle pro ...... emporary prostatectomy cohort.
@en
P2093
Alexander Gutin
Azita Djalilvand
Gregory P Swanson
Janet E Cowan
Jeffry P Simko
Jerry S Lanchbury
Julia E Reid
Peter R Carroll
Satish Bhatnagar
Steven Stone
P304
P356
10.1200/JCO.2012.46.4396
P407
P577
2013-03-04T00:00:00Z